X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.
Jacoti is kicking off the launch of its smartphone-enabled hearing aid, ListenApp. It modifies the sound using software installed into an iPhone.
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Google's secretive Calico signed yet another partnership with a world-class research outfit, this time divulging some details that could provide clues on how it plans to attack aging.
Cardio3 Biosciences is set to become the latest European biotech to pitch up on Wall Street in search of cash from public investors. And with a clinical-phase CAR-T asset in its pipeline, the Belgian biotech stands a chance of tapping into investor enthusiasm for the red-hot niche.
Ken Drazan, head of J&J Innovation's California outpost, joins FierceBiotech Radio to discuss how the pharma giant approaches external R&D, how partnering has changed in modern biopharma and why med tech so often lags other fields in life sciences.
Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
MultiVir, a developer of viral vectors to deliver anticancer gene therapy, just filed for a $70 million IPO with the Securities and Exchange Commission as it seeks funding for clinical trials of its Phase I/II lead candidates for colorectal cancer and head and neck cancer, and to take the first FDA-approved gene therapy to the market.
Bayer is deepening its ties with Harvard and MIT's Broad Institute, delving into cardiovascular genomics in hopes of spotlighting new therapeutic approaches to deadly diseases.